Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
Merck & Co., Inc. (MRK) announced positive Phase 3 CORALreef AddOn trial results for its investigational once-daily oral PCSK9 inhibitor, enlicitide decanoate. The drug significantly reduced LDL-C by 64.6% and surpassed other therapies in helping patients achieve target LDL-C levels, with a consistent safety profile. This development follows Merck’s recent $6.7 billion acquisition of Terns Pharmaceuticals, Inc. to expand its oncology portfolio.